HDAC5, an early osimertinib-responsive gene, is a novel therapeutic target for the drug resistance in EGFR-mutant lung adenocarcinoma cells.
HDAC5 是一种早期对奥希替尼有反应的基因，是治疗 EGFR 突变肺腺癌细胞耐药性的新型治疗靶点
期刊:Biochemistry and Biophysics Reports
影响因子:2.2
doi:10.1016/j.bbrep.2025.102016
Lyu Hanbing, Ishimura Akihiko, Suzuki Ryusuke, Buyanbat Khurelsukh, Batbayar Gerelsuren, Meguro-Horike Makiko, Horike Shin-Ichi, Yano Seiji, Suzuki Takeshi
